Published in final edited form as:

J Pain. 2012 January ; 13(1): 64–72. doi:10.1016/j.jpain.2011.10.007.

Predictors of Change in Pain and Physical Functioning among Post-Menopausal Women with Recurrent Pain Conditions in the Women's Health Initiative Observational Cohort

Jennifer Brennan Braden, MD, MPH^{*}, Alicia Young, MS[†], Mark D. Sullivan, MD, PhD^{*}, Brian Walitt, MD, MPH[‡], Andrea Z. LaCroix, PhD^{†,§}, and Lisa Martin, MD^{||}

^{*}Department of Psychiatry & Behavioral Sciences, University of Washington School of Medicine, Seattle, WA

[†]Fred Hutchinson Cancer Research Center, Seattle, WA

[§]University of Washington Department of Epidemiology, Seattle, WA

[‡]Washington Hospital Center, Washington D.C

^{||}Department of Medicine, George Washington University, Washington, DC

Abstract

Pain complaints are commonly reported symptoms among postmenopausal women and can have significant effects on health-related quality of life. We sought to identify medical and psychosocial factors that predict changes in pain and overall physical functioning over a three-year period among post-menopausal women with recurrent pain conditions. We examined data from postmenopausal women age 50–79 with recurrent pain conditions (low back pain, neck pain, headache or migraines, or joint pain or stiffness) over a three-year period using the Women's Health Initiative Observational Study Cohort (N=67,963). Multinomial logistic regression models controlling for demographic and clinical characteristics were used to identify baseline predictors of change in the SF-36 subscales for pain and physical functioning between baseline and three year follow-up. BMI was associated with worsening of pain (OR [95% CI] 1.54 [1.45–1.63] for BMI ≥30) and physical functioning (1.83 [1.71–1.95] for BMI ≥30). A higher reported number of non-pain symptoms, higher medical comorbidity and a positive screen for depression (1.13 [1.05–1.22] for worsened pain) were also associated with worsening of pain and physical functioning. Baseline prescription opioid use was also associated with lack of improvement in pain (OR 0.42, 95% CI 0.36–0.49) and with worsened physical functioning (1.25 [1.04–1.51]).

© 2011 The American Pain Society. Published by Elsevier Inc. All rights reserved.

Corresponding author: Jennifer Brennan Braden, MD, MPH, Affiliate Assistant Professor, Psychiatry and Behavioral Sciences, University of Washington, Box 356560, Seattle, WA 98195, Phone: 425-656-4055 Fax: 425-656-5425, jkbrenn@uw.edu.

All of the authors report no conflicts of interest.

Disclosures

The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221. Dr. Braden was supported by a Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant [T32 MH20021 (Katon)].

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

pain; opioid; women; longitudinal cohort; obesity

Introduction

The prevalence of persistent pain complaints is higher among women than among men and increases with age^{7,47,53}. Pain complaints are commonly reported symptoms among women in midlife and later^{9,20,24,25} and along with other complaints such as vasomotor symptoms, depression and sleep disturbance, can have significant effects on health-related quality of life^{3,18,52}. For example, approximately half of perimenopausal or post-menopausal women age 45 to 50 in the Australian Longitudinal Study on Women's Health endorsed back pain, headaches or joint pain⁹. In both the Penn Ovarian Aging Study and the Study of Women's Health Across the Nation (SWAN), approximately three-fourths of women endorsed joint pain or stiffness^{20,24}. In the SWAN study, approximately one quarter reported these symptoms as moderate to severe intensity. While headaches have been reported to decrease in the transition to menopause²⁴, joint pain tends to increase^{20,25}. This finding is consistent with surveys of older adults (men and women), where about half report experiencing joint pain compared to one-quarter to one-third of younger adults^{7,40}.

Psychological symptoms have been associated with persistent pain. Depression has been shown to both precede and follow the development of pain^{19,42}, and the co-occurrence of depression and pain is associated with worse physical and emotional functioning in cross-sectional studies^{2,7,8}. Depression has been reported to be positively associated with higher subjective levels of pain interference both in the broader pain population^{2,8} and in menopausal women specifically⁴⁹. Anger and hostility have been associated with poor pain treatment outcomes, and ambivalence over emotional expression (AEE), the tendency to be conflicted about expressing one's emotions, may be linked to increased pain^{11,13,22,36}. In a recent study of chronic low back pain patients, patients scoring high on AEE were much more likely to report higher pain on the affective and evaluative pain scales of the McGill Pain Questionnaire¹³. In a longitudinal study of 169 continuing care retirement community residents, the percent with any pain increased 6.5% over the 24-month period; the percent with pain without activity limitations remained relatively stable, but the percent with pain with activity limitations increased from 35.5 to 42.2%³⁹. Psychiatric comorbidity, poor pain coping behaviors, high baseline functional impairment and low general health status have been shown to be predictive of persistent disabling back pain one year later among those with fewer than eight weeks of low back pain¹⁵. Little is known, however, about the longitudinal course and modifiers of pain in the general population or in postmenopausal women specifically.

In this study, we sought to identify psychosocial, demographic and clinical factors that predict changes in pain and overall physical functioning over a three-year period among post-menopausal women with recurrent pain conditions using data from the Women's Health Initiative Observational Cohort. The subpopulation of patients with non-cancer pain receiving opioid therapy is of special interest, given the marked increase in use of these drugs for non-cancer pain over the past 30 years. Individuals with depression are more likely to be prescribed opioids for non-cancer pain than those without depression^{6,21,48}, and post-menopausal women may be more likely to receive opioids than younger women for non-cancer pain given the health risks associated with COX-2 inhibitors and non-steroidal anti-inflammatory drugs^{1,12}. Hence, we included use of regular prescription opioids as one of the clinical factors examined in our study.

Materials and Methods

Population

Data are from the Women's Health Initiative Observational Study Cohort. The Women's Health Initiative is a national health study consisting of a set of randomized controlled trials and an observational study. The Observational Study Cohort followed 93,676 postmenopausal women age 50–79 for a period of eight to 12 years starting in 1998. Women were eligible if they were age 50–79, postmenopausal, had ability and willingness to provide written informed consent, and intention to reside in the area for at least three years. Women were excluded if they had a medical condition with predicted survival of less than three years, or mental disorders that might interfere with adherence or retention in the study (assessed by asking potential study participants, “Are there any reasons, like serious emotional problems, mental illness, or too much stress, that would make it hard for you to be in a research study?”). Women screened for participation in the clinical trials but unwilling or ineligible (i.e. because of the presence of a health condition that was a competing risk factor or safety concern for trial outcomes), were offered the opportunity to participate in the Observational Study Cohort. Participants completed questionnaires and provided blood specimens and physical measurements at the baseline screening visit and returned for a second visit three years later. Informed consent from each participant was obtained, and human subjects review committees at each participating institution approved the study. Analyses for this study were limited to the subset of women in the Observational Study Cohort with “recurrent pain,” defined as endorsing low back pain, neck pain, headache or migraines, or joint pain or stiffness in the prior four weeks at both the baseline and three-year follow-up visits (N=67,963). Details about the design of the WHI can be found elsewhere^{30,43}.

Variables

Participants were asked to indicate the presence and severity of 34 symptoms of distress (scale of 0=symptom did not occur to 3=severe) in the prior four weeks at baseline and follow-up visits. The list of symptoms was obtained from the Postmenopausal Estrogen/ Progestin Intervention study and from other national health surveys. Those who responded ≥ 1 for low back pain, neck pain, headache/migraine, or joint pain/stiffness at both baseline and follow-up visits were defined as having recurrent pain. Responses to the other items were summed to create a measure of the number of non-pain symptoms. Pain severity and pain interference in the prior four weeks were assessed via a Likert scale (pain severity: 0=none to 5=severe; pain interference: 1=not at all to 5=extremely) using questions from the Short Form (SF)-36⁵⁵, and averaged to create one pain score (i.e. the SF-36 pain subscale). Physical functioning was assessed using the physical functioning subscale of the SF-36. Scores were converted to a scale ranging from 0 and 100, with a higher score indicating a more favorable health state. Changes in pain and physical functioning were determined by subtracting the numerical score at baseline from that at year three for each respondent. For the sake of clarity, moving to a more favorable health state between baseline and year 3 (i.e., decrease in pain, increase in physical functioning) was defined as “improved” and moving to a less favorable health state between baseline and year 3 (i.e., increase in pain, decrease in physical functioning) was defined as “worsened.” Medical comorbidity was assessed with the Charlson comorbidity index¹⁴. Hours per day of sedentary activity was obtained by self report and defined as hours sleeping, sitting or lying down. Participants were asked about use of medications for two weeks or more, along with duration of use. Opioid use was defined as use of DEA Schedule II-V prescription opioids. Other analgesic use was defined as use of acetaminophen, ibuprofen and other non-steroidal anti-inflammatories, aspirin, salicylate analgesics, other aspirin like analgesics, lidocaine and capsaicin creams. Use of hormone replacement therapy (HT) was assessed by a series of questions about use of

hormone medications for relief of menopausal symptoms, following hysterectomy with removal of the ovaries, or for prevention of disease such as bone loss. Body mass index (BMI) was calculated from height and weight measurements obtained at the baseline visit (weight in kilograms/height in meters²). For analysis purposes, BMI was divided into three categories to correspond with normal, overweight and obese: <25, 25–<30, ≥30. Demographic characteristics and disability status were obtained by self report.

Depression was assessed with the Burman scale¹⁰, a shortened form of the CES-D that has been validated in a large study of office-based practices. Respondents with scores ≥0.06 were considered to be depressed. Social support was assessed by nine questions from the Medical Outcomes Study⁴⁵. Possible scores ranged from 9–45, with a higher score indicating greater support. The Ambivalence Over Emotional Expression Questionnaire was used to assess the relationship between negative emotion and health outcomes³⁵. The questionnaire consists of three items (e.g. after I express anger at someone, it bothers me for a long time); possible scores range from 1–5, with higher scores indicating greater ambivalence in expressing negative emotions. Cynicism was measured using the 13-item cynicism subscale of the Cook-Medley Hostility Questionnaire (example items: no one cares much what happens to you; I think most people would lie to get ahead); possible scores ranged from 0–13, with higher scores indicating greater cynicism⁵.

Statistical Analyses

Demographic and clinical variables were analyzed descriptively using frequencies and percents for categorical variables and means with standard deviations for continuous variables, stratified by change in pain between baseline and year 3 (no change, worsened, improved pain). Chi-square tests were performed for categorical variables, and one-way ANOVA tests were performed for continuous variables to assess differences among groups. Multinomial logistic regression models were used to identify predictors of change in pain and physical functioning between baseline and three year follow-up, while controlling for demographic (age at screening, highest education level, family income, employment status-disabled, race/ethnicity) and clinical characteristics (BMI, Charlson index, number of non-pain symptoms, HT use, baseline pain or physical functioning) at baseline. Specifically, the models examined the association between the independent variables and 1) increase in pain (i.e. worsening) versus no change in pain 2) decrease in pain (i.e. improvement) versus no change in pain 3) increase in physical functioning (i.e. improvement) versus no change in physical functioning and 4) decrease in physical functioning (i.e. worsening) versus no change in physical functioning between baseline and year 3. Independent variables in the regression models included opioid use, the presence of depression, ambivalence over emotional expressiveness, hostility, social support, and hours of sedentary activity per day. Data from participants with missing values for one or more covariates in the models was excluded from the regression analyses, leaving a total of 51839 participants for the model with outcome change in pain and 50849 for the model with outcome change in physical functioning.

Results

Of the 93,676 women enrolled in the WHI OS, 67963 met the criteria for recurrent pain and were included in the analyses for this study. An additional 9774 reported pain at baseline and were missing the pain measures at Year 3, and another 4584 reported pain at baseline and not at Year 3.

Sociodemographic and Clinical Characteristics

Table 1 presents the demographic and clinical characteristics of the cohort with recurrent pain, stratified by whether they experienced a worsening, improvement or no change in pain between baseline and year 3. In general, the women were primarily White, had at least a high school diploma, an annual family income >\$35,000, a mean age of 63–64 years, and a mean BMI in the overweight range. The majority of the women reported at least mild joint pain or stiffness; the next most common pain condition reported was low back pain. Most women (56017 [82%]) reported more than one pain type. Mean baseline scores for pain and physical functioning were higher among those reporting no change or worsened pain between baseline and year 3. Nearly half of the women (43.9%, n=29,721) reported use of a non-opioid analgesic. 4.3% (2914) reported prescription opioid use: 2.3% (1582) at baseline, 2.0% (1332) at year 3 only and 0.9% (615) at baseline and year 3. Most women with baseline opioid use had use for >90 days (83%, n=1325). The median duration of those reporting opioid use at baseline was 2 years, and at year 3 was 1.5 years. Approximately 11% of women screened positive for depression on the Burman (shortened CES-D) scale (score $\geq$ 0.06); average scores for ambivalence over emotional expressiveness and cynicism were low, and for social support were high.

Women with any prescription opioid use at baseline differed from women with no opioid use at baseline on all variables examined. They tended to have worse pain scores (mean [SD] 41 [25.2] vs. 72.6 [22.6].), a higher number of non-pain medical conditions (11 [5.2] vs. 8.9 [4.6]), a higher Charlson score (1.3 [1.4] vs. 0.8 [1.1]), lower physical functioning (56.8 [26.7] vs. 80.6 [19.7]), slightly higher BMI (29.5 [6.9] vs. 27.3 [5.8]), were more likely to be disabled (13.5% vs. 1.9%) and were more likely to screen positive for depression (20.5% vs. 11.1%) ($p<0.001$ for all differences noted). Women with baseline opioid use also were more likely to report having each of the four pain symptoms examined in our study than those without baseline opioid use. The most common pain type reported by those with baseline opioid use was low back pain (80.6%, n=1272).

Logistic Regression Models

Tables 2 and 3 present results from multinomial logistic regression models examining variables associated with change in pain and physical functioning between baseline and year 3 among women with recurrent pain conditions. The effect size of many of the covariates tended to be small, particularly for the psychosocial variables other than depression.

Table 2: Change in Pain

Baseline opioid use (OR [95% CI] 0.42 (0.36, 0.49), $p<.001$; and being disabled at baseline (0.37 (0.31, 0.44) were strongly associated with a lack of improvement (i.e. decreased odds of improvement vs. no change) in pain. BMI ≥ 30 vs. <25 (1.54 (1.45,1.63) was strongly associated with a worsening in pain.

A positive screen for depression, baseline hormone therapy use, higher Charlson index score, and higher number of non-pain symptoms were all associated with lack of improvement and worsening of pain between baseline and year 3. More social support was associated with decreased likelihood of worsening of pain. We also ran the regression model including the different pain types (i.e. joint pain or stiffness, low back pain, neck pain, migraine or headaches) as additional covariates. We did this as a sensitivity analysis to rule out potential confounding of the results for baseline opioid use by responsiveness of pain type to prescription opioid treatment. Results for the model were not significantly changed by this addition. All of the pain types were associated with worse pain and lack of improvement between baseline and year 3, with the exception that migraines or headaches were not significantly associated with worsening of pain.

Table 3: Change in Physical Functioning

BMI ≥ 30 vs. < 25 (OR [95% CI] 1.83 [1.71–1.95]) was strongly associated with worsened physical functioning between baseline and year 3. Being disabled at baseline was strongly associated with lack of improvement in physical functioning (0.39 [0.31, 0.49]). A positive screen for depression, increased hours of sedentary activity per day, higher ambivalence over emotional expressiveness score, baseline hormone therapy use, higher Charlson index score, higher number of non-pain symptoms, and baseline opioid use were associated with a worsening of physical functioning between baseline and year 3. More social support was associated with decreased likelihood of worsened physical functioning.

Discussion

In this longitudinal study of 67,963 postmenopausal women with recurrent pain, we examined demographic, medical, and psychosocial variables associated with change in pain and physical functioning over three years of follow up. To the best of our knowledge this is the largest prospective observational study to look at factors associated with change in pain. Previous prospective studies have focused primarily on recovery after acute trauma or injury^{17,44,46}. In our study, recurrent pain was very common among study participants, endorsed by nearly three-fourths. This is consistent with prior studies reporting the prevalence of pain complaints among postmenopausal women^{9,20,24}, and extends these findings by demonstrating the recurrence of pain over a several year period in this population. Almost 40% of the women in our study reported worse pain at year 3 compared to baseline. BMI in the overweight or obese range (≥ 25) was associated with worsened pain and physical functioning at year 3 and the associations were greatest in those with BMI ≥ 30 . Prior cross-sectional studies have demonstrated an association between chronic pain and obesity^{32,37,50,56} and prospective studies suggest that overweight/obesity early in life is a risk factor for development of pain³³. In the Longitudinal Aging Amsterdam Study, adults age 55–85 years in the highest quartile of BMI had a twofold increased odds for incident pain after 3 years of follow-up³¹. Our study results are consistent with these findings and add to them by suggesting that elevated BMI also is associated with worsening of pre-existing pain conditions over time.

Even after controlling for baseline pain, pain type and depression, women reporting prescription opioid use at baseline were more likely to report lack of improvement in pain and worsened physical functioning three years later. It is possible that the women reporting prescription opioid use had pain that was both more severe and more difficult to treat. Nearly all the women in our study with baseline opioid use reported use for 90 days or longer, suggesting they were receiving chronic opioid therapy for a chronic pain condition. Meta-analyses have shown opioids to be more effective than placebo for treatment of chronic pain over 12 weeks of therapy²⁶, but there are no controlled trials that examine efficacy over years of therapy. A large cross-sectional observational study in Denmark showed higher pain intensity, pain interference, and worse quality of life for patients treated with opioids than those not treated with opioids, but it was not possible to rule out selection bias in this study²³. There also is some evidence that longer term use of opioids could be associated with the development of hyperalgesia, increased sensitivity to pain^{16,51}. Individuals receiving prescription opioids had higher baseline pain which could result in decreased physical activity levels and subsequent weight gain, further worsening pain and overall physical functioning. Consistent with this assessment, more hours per day of sedentary activity at baseline was associated with a worsening of physical functioning at year 3. Being disabled at baseline was also associated with lack of improvement in pain over the three-year period, and may similarly reflect a subpopulation more refractory to treatment. Results from our study highlight the need for clinical effectiveness studies to evaluate the long-term

use and tolerability of prescription opioids, and to evaluate functional outcomes, in the treatment of recurrent pain among postmenopausal women.

The non-pain symptom count captured information on symptoms of distress that might be obtained in a review of symptoms, e.g. nausea, hot flashes, dizziness, fatigue, and was associated with worse pain outcomes over the three year period. This variable reflects overall symptom burden and is associated with both medical and psychiatric comorbidity³⁴. Results from our study are consistent with prior studies, which have found a positive association between elevated levels of non-specific physical symptoms and pain severity, negative affect and disability among individuals with chronic pain^{38,41,54}. The association between baseline hormone therapy use and worse pain outcomes may reflect use of HRT to treat postmenopausal symptoms, which include pain (e.g. joint and back pain), as well as non-pain symptoms (e.g. fatigue, mood lability, sleep disturbance, memory changes, night sweats).

One of the primary objectives of our study was to examine psychosocial predictors of a change in pain interference, pain severity and physical functioning. Prior cross-sectional studies have shown an association between depression and higher pain interference and severity^{2,4,8} and prospective studies have found that depression and persistent pain equally predict the subsequent onset of the other²⁷. Consistent with this, a positive screen for depression at baseline was associated with worsening of pain at year 3 among women in our study. The association was modest, possibly reflecting the healthier baseline mental health status of the study population in comparison with clinical populations. In addition, the shortened CES-D screening instrument used in this study is less specific than the full CES-D or a diagnostic interview, and thus women screening positive likely included some with more minor depressive symptoms that would not necessarily prompt help-seeking or clinical intervention. Ambivalence over emotional expression and cynicism were not consistent or strong predictors of pain outcomes. This may be because the women in this study had relatively low baseline scores on these construct measures.

Strengths of our study include the large population-based sample with longitudinal follow-up and availability of data on a variety of psychosocial, medication use and medical variables. There are several limitations to our study that should be mentioned. The data available on prescription opioid use from this study was limited to self report of duration of use at the baseline and year 3 interviews. Hence, we are unable to determine whether use continued between the two interviews, and we lack data on prescribed dose. In addition, because this is an observational study and opioid use was obtained by self report, we cannot verify what pain condition the opioids were prescribed to treat. We also are unable to rule out the possibility that patients selected for opioid therapy had more progressive pain problems. Information on pain conditions and depressive symptoms were based on self report, not diagnoses from a health care provider or via a structured diagnostic interview. In addition, we lacked information on anxiety, which has previously been shown to be associated with persistent pain^{47,53}, and illicit drug or alcohol use, as well as information on the presence and severity of pain complaints at time points between the baseline and year 3 interviews. Pain complaints included in the definition of recurrent pain were limited to four of the more common conditions seen in primary care²⁸, but did not include others of clinical importance, such as fibromyalgia. The study population consisted of primarily White, middle-class postmenopausal women and results therefore may not be generalizable to all individuals with recurrent pain conditions.

In summary, elevated BMI in the overweight/obese range, a positive screen for depression, higher medical comorbidity and number of non-pain symptoms were all associated with worsening pain and physical functioning over a three-year period in this cohort of

postmenopausal women with recurrent pain conditions. Baseline prescription opioid use was not associated with worsening pain but was associated with lack of improvement in pain and with worsened physical functioning at year 3. This is consistent with concerns of some experts that long-term opioid use may decrease physical function by promoting rest or inactivity²⁹.

While it is impossible to rule out selection bias in opioid prescription in this observational study, results suggest further inquiry into the efficacy and tolerability of opioid treatment in this population is warranted. Results support prior recommendations to screen for and treat depression among those with recurrent pain conditions⁵¹ and highlight the role of obesity and weight management in long-term pain outcomes. In addition, results suggest that individuals reporting multiple physical symptoms in addition to pain are at risk for worsening pain over time. Additional prospective and comparative effectiveness studies are needed to further examine the effects of obesity, depression and opioid therapy on the course of recurrent pain conditions.

Acknowledgments

Short list of WHI investigators:

Program Office: (National Heart, Lung, and Blood Institute, Bethesda, Maryland) Jacques Rossouw, Shari Ludlam, Joan McGowan, Leslie Ford, and Nancy Geller

Clinical Coordinating Center: Clinical Coordinating Center: (Fred Hutchinson Cancer Research Center, Seattle, WA) Garnet Anderson, Ross Prentice, Andrea LaCroix, and Charles Kooperberg

Investigators and Academic Centers: (Brigham and Women's Hospital, Harvard Medical School, Boston, MA) JoAnn E. Manson; (MedStar Health Research Institute/Howard University, Washington, DC) Barbara V. Howard; (Stanford Prevention Research Center, Stanford, CA) Marcia L. Stefanick; (The Ohio State University, Columbus, OH) Rebecca Jackson; (University of Arizona, Tucson/Phoenix, AZ) Cynthia A. Thomson; (University at Buffalo, Buffalo, NY) Jean Wactawski-Wende; (University of Florida, Gainesville/Jacksonville, FL) Marian Limacher; (University of Iowa, Iowa City/Davenport, IA) Robert Wallace; (University of Pittsburgh, Pittsburgh, PA) Lewis Kuller; (Wake Forest University School of Medicine, Winston-Salem, NC) Sally Shumaker

Women's Health Initiative Memory Study: (Wake Forest University School of Medicine, Winston-Salem, NC) Sally Shumaker

References

1. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA, Association AH. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. *Circulation*. 2007; 115:1634–1642. [PubMed: 17325246]
2. Arnow BA, Hunkeler EM, Blasey CM, Lee J, Constantino MJ, Fireman B, Kraemer HC, Dea R, Robinson R, Hayward C. Comorbid depression, chronic pain, and disability in primary care. *Psychosom Med*. 2006; 68:262–268. [PubMed: 16554392]
3. Avis NE, Colvin A, Bromberger JT, Hess R, Matthews KA, Ory M, Schocken M. Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged women: Study of Women's Health Across the Nation. *Menopause*. 2009
4. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. *Arch Intern Med*. 2003; 163:2433–2445. [PubMed: 14609780]
5. Barefoot JC, Dodge KA, Peterson BL, Dahlstrom WG, Williams RB Jr. The Cook-Medley hostility scale: item content and ability to predict survival. *Psychosom Med*. 1989; 51:46–57. [PubMed: 2928460]
6. Braden JB, Sullivan MD, Ray GT, Saunders K, Merrill J, Silverberg MJ, Rutter CM, Weisner C, Banta-Green C, Campbell C, Von Korff M. Trends in long-term opioid therapy for noncancer pain among persons with a history of depression. *Gen Hosp Psychiatry*. 2009; 31:564–570. [PubMed: 19892215]

7. Braden JB, Zhang L, Fan MY, Unutzer J, Edlund MJ, Sullivan MD. Mental health service use by older adults: the role of chronic pain. *Am J Geriatr Psychiatry*. 2008; 16:156–167. [PubMed: 18192496]
8. Braden JB, Zhang L, Zimmerman FJ, Sullivan MD. Employment outcomes of persons with a mental disorder and comorbid chronic pain. *Psychiatr Serv*. 2008; 59:878–885. [PubMed: 18678685]
9. Brown WJ, Mishra GD, Dobson A. Changes in physical symptoms during the menopause transition. *Int J Behav Med*. 2002; 9:53–67. [PubMed: 12112996]
10. Burman MA, Wells KB, Leake B, Landsverk J. Development of a brief screening instrument for detecting depressive disorders. *Medical Care*. 1988; 26:8.
11. Burns JW, Johnson BJ, Devine J, Mahoney N, Pawl R. Anger management style and the prediction of treatment outcome among male and female chronic pain patients. *Behav Res Ther*. 1998; 36:1051–1062. [PubMed: 9737057]
12. Campbell CI, Weisner C, Leresche L, Ray GT, Saunders K, Sullivan MD, Banta-Green CJ, Merrill JO, Silverberg MJ, Boudreau D, Satre DD, Von Korff M. Age and gender trends in long-term opioid analgesic use for noncancer pain. *Am J Public Health*. 2010; 100:2541–2547. [PubMed: 20724688]
13. Carson JW, Keefe FJ, Lowry KP, Porter LS, Goli V, Fras AM. Conflict about expressing emotions and chronic low back pain: associations with pain and anger. *J Pain*. 2007; 8:405–411. [PubMed: 17276143]
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987; 40:373–383. [PubMed: 3558716]
15. Chou R, Shekelle P. Will this patient develop persistent disabling low back pain? *JAMA*. 2010; 303:1295–1302. [PubMed: 20371789]
16. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. *J Pain*. 2006; 7:43–48. [PubMed: 16414554]
17. Clay FJ, Newstead SV, Watson WL, Ozanne-Smith J, Guy J, McClure RJ. Bio-psychosocial determinants of persistent pain 6 months after non-life-threatening acute orthopaedic trauma. *J Pain*. 2010; 11:420–430. [PubMed: 20439055]
18. Dennerstein L, Leher P, Guthrie JR, Burger HG. Modeling women's health during the menopausal transition: a longitudinal analysis. *Menopause*. 2007; 14:53–62. [PubMed: 17023873]
19. Dersh J, Mayer T, Theodore BR, Polatin P, Gatchel RJ. Do psychiatric disorders first appear preinjury or postinjury in chronic disabling occupational spinal disorders? *Spine*. 2007; 32:1045–1051. [PubMed: 17450081]
20. Dugan SA, Powell LH, Kravitz HM, Everson Rose SA, Karavolos K, Luborsky J. Musculoskeletal pain and menopausal status. *Clin J Pain*. 2006; 22:325–331. [PubMed: 16691084]
21. Edlund MJ, Martin BC, Devries A, Fan MY, Braden JB, Sullivan MD. Trends in use of opioids for chronic noncancer pain among individuals with mental health and substance use disorders: the TROUP study. *Clin J Pain*. 2010; 26:1–8. [PubMed: 20026946]
22. Epker J, Block AR. Presurgical psychological screening in back pain patients: a review. *Clin J Pain*. 2001; 17:200–205. [PubMed: 11587109]
23. Eriksen J, Sjøgren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. *Pain*. 2006; 125:172–179. [PubMed: 16842922]
24. Freeman EW, Sammel MD, Lin H, Gracia CR, Kapoor S. Symptoms in the menopausal transition: hormone and behavioral correlates. *Obstet Gynecol*. 2008; 111:127–136. [PubMed: 18165401]
25. Freeman EW, Sammel MD, Lin H, Gracia CR, Pien GW, Nelson DB, Sheng L. Symptoms associated with menopausal transition and reproductive hormones in midlife women. *Obstet Gynecol*. 2007; 110:230–240. [PubMed: 17666595]
26. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. *Cmaj*. 2006; 174:1589–1594. [PubMed: 16717269]
27. Gureje O, Simon GE, Von Korff M. A cross-national study of the course of persistent pain in primary care. *Pain*. 2001; 92:195–200. [PubMed: 11323140]

28. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization Study in Primary Care. *JAMA*. 1998; 280:147–151. [PubMed: 9669787]
29. Harden RN. Chronic pain and opiates: a call for moderation. *Arch Phys Med Rehabil*. 2008; 89:S72–76. [PubMed: 18295654]
30. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, Rossouw JE. The Women's Health Initiative recruitment methods and results. *Ann Epidemiol*. 2003; 13:S18–77. [PubMed: 14575939]
31. Heim N, Snijder MB, Deeg DJ, Seidell JC, Visser M. Obesity in older adults is associated with an increased prevalence and incidence of pain. *Obesity (Silver Spring)*. 2008; 16:2510–2517. [PubMed: 18787527]
32. Hitt HC, McMillen RC, Thornton-Neaves T, Koch K, Cosby AG. Comorbidity of obesity and pain in a general population: results from the Southern Pain Prevalence Study. *J Pain*. 2007; 8:430–436. [PubMed: 17337251]
33. Janke EA, Collins A, Kozak AT. Overview of the relationship between pain and obesity: What do we know? Where do we go next? *J Rehabil Res Dev*. 2007; 44:245–262. [PubMed: 17551876]
34. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. *Biol Psychiatry*. 2003; 54:216–226. [PubMed: 12893098]
35. King LA, Emmons RA. Conflict over emotional expression: psychological and physical correlates. *J Pers Soc Psychol*. 1990; 58:864–877. [PubMed: 2348373]
36. Lombardo ER, Tan G, Jensen MP, Anderson KO. Anger management style and associations with self-efficacy and pain in male veterans. *J Pain*. 2005; 6:765–770. [PubMed: 16275601]
37. McCarthy LH, Bigal ME, Katz M, Derby C, Lipton RB. Chronic pain and obesity in elderly people: results from the Einstein aging study. *J Am Geriatr Soc*. 2009; 57:115–119. [PubMed: 19054178]
38. McCracken LM, Faber SD, Janeck AS. Pain-related anxiety predicts non-specific physical complaints in persons with chronic pain. *Behav Res Ther*. 1998; 36:621–630. [PubMed: 9648335]
39. Mossey JM, Gallagher RM. The longitudinal occurrence and impact of comorbid chronic pain and chronic depression over two years in continuing care retirement community residents. *Pain Med*. 2004; 5:335–348. [PubMed: 15563319]
40. National Center for Health Statistics. Health, United States. With Chartbook on Trends in the Health of Americans. Hyattsville, MD: 2006.
41. O'Brien EM, Atchison JW, Gremillion HA, Waxenberg LB, Robinson ME. Somatic focus/awareness: Relationship to negative affect and pain in chronic pain patients. *Eur J Pain*. 2008; 12:104–115. [PubMed: 17524684]
42. Polatin PB, Kinney RK, Gatchel RJ, Lillo E, Mayer TG. Psychiatric illness and chronic low-back pain. The mind and the spine--which goes first? *Spine*. 1993; 18:66–71. [PubMed: 8434327]
43. Prentice R, Rossouw J, Furberg C, Johnson S, Henderson M, Cummings S, Manson J, Freedman L, Oberman A, Kuller L, Anderson G. Design of the WHI Clinical Trial and Observational Study. *Control Clin Trials*. 1998; 19:61–109. [PubMed: 9492970]
44. Rivara FP, Mackenzie EJ, Jurkovich GJ, Nathens AB, Wang J, Scharfstein DO. Prevalence of pain in patients 1 year after major trauma. *Arch Surg*. 2008; 143:282–287. discussion 288. [PubMed: 18347276]
45. Sherbourne CD, Stewart AL. The MOS social support survey. *Soc Sci Med*. 1991; 32:705–714. [PubMed: 2035047]
46. Stålnacke BM. Relationship between symptoms and psychological factors five years after whiplash injury. *J Rehabil Med*. 2009; 41:353–359. [PubMed: 19363569]
47. Stang PE, Brandenburg NA, Lane MC, Merikangas KR, Von Korff MR, Kessler RC. Mental and physical comorbid conditions and days in role among persons with arthritis. *Psychosom Med*. 2006; 68:152–158. [PubMed: 16449426]
48. Sullivan MD, Edlund MJ, Steffick D, Unutzer J. Regular use of prescribed opioids: association with common psychiatric disorders. *Pain*. 2005; 119:95–103. [PubMed: 16298066]
49. Szoek CE, Cicuttini FM, Guthrie JR, Dennerstein L. The relationship of reports of aches and joint pains to the menopausal transition: a longitudinal study. *Climacteric*. 2008; 11:55–62. [PubMed: 18202965]

50. Toblin RL, Mack KA, Perveen G, Paulozzi LJ. A population-based survey of chronic pain and its treatment with prescription drugs. *Pain*. 2011
51. Trescot AM, Boswell MV, Atluri SL, Hansen HC, Deer TR, Abdi S, Jasper JF, Singh V, Jordan AE, Johnson BW, Cicala RS, Dunbar EE, Helm S 2nd, Varley KG, Suchdev PK, Swicegood JR, Calodney AK, Ogoke BA, Minore WS, Manchikanti L. Opioid guidelines in the management of chronic non-cancer pain. *Pain Physician*. 2006; 9:1–39. [PubMed: 16700278]
52. Vogt MT, Lauerman WC, Chirumbole M, Kuller LH. A community-based study of postmenopausal white women with back and leg pain: health status and limitations in physical activity. *J Gerontol A Biol Sci Med Sci*. 2002; 57:M544–550. [PubMed: 12145370]
53. Von Korff M, Crane P, Lane M, Miglioretti DL, Simon G, Saunders K, Stang P, Brandenburg N, Kessler R. Chronic spinal pain and physical-mental comorbidity in the United States: results from the national comorbidity survey replication. *Pain*. 2005; 113:331–339. [PubMed: 15661441]
54. Von Korff M, Dworkin SF, Le Resche L, Kruger A. An epidemiologic comparison of pain complaints. *Pain*. 1988; 32:173–183. [PubMed: 3362555]
55. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992; 30:473–483. [PubMed: 1593914]
56. Wright LJ, Schur E, Noonan C, Ahumada S, Buchwald D, Afari N. Chronic pain, overweight, and obesity: findings from a community-based twin registry. *J Pain*. 2011; 11:628–635. [PubMed: 20338816]

Perspective

This study presents prospective data on change in pain and physical functioning in postmenopausal women over a three-year period. Our results suggest depression, non-pain physical symptoms, obesity and possibly opioid treatment are associated with worse long-term pain outcomes in this population.

Sociodemographic and Clinical Characteristics at Baseline of Post-Menopausal Women with Recurrent Pain Conditions 3-Years Later

Table 1

Characteristics	Change in Pain Baseline to 3-Year Follow-Up			
	Improved (N=20742)	None (N=20163)	Worsened (N=26647)	P-value
Sociodemographic				
Age at screening, mean (SD)	63 (7.3)	63 (7.2)	64 (7.3)	< 0.001
Racial/ethnic group, N (%)				
White	17542 (84.6%)	17447 (86.5%)	22749 (85.4%)	< 0.001
Black	1524 (7.3%)	1276 (6.3%)	1909 (7.2%)	
Hispanic	759 (3.7%)	550 (2.7%)	838 (3.1%)	
American Indian	90 (0.4%)	59 (0.3%)	112 (0.4%)	
Asian/Pacific Islander	538 (2.6%)	578 (2.9%)	671 (2.5%)	
Unknown	289 (1.4%)	253 (1.3%)	368 (1.4%)	
Highest education level				
0–8 years	314 (1.5%)	175 (0.9%)	380 (1.4%)	< 0.001
Some high school	704 (3.4%)	545 (2.7%)	923 (3.5%)	
High school diploma/GED	3279 (15.8%)	3183 (15.8%)	4532 (17.0%)	
School after high school	7708 (37.2%)	7213 (35.8%)	9972 (37.4%)	
College degree or higher	8569 (41.3%)	8907 (44.2%)	10635 (39.9%)	
Total family income*				
< \$10,000	781 (3.8%)	617 (3.1%)	1053 (4.0%)	< 0.001
\$10,000 – \$19,999	2229 (10.7%)	1907 (9.5%)	2997 (11.2%)	
\$20,000 – \$34,999	4583 (22.1%)	4143 (20.5%)	6113 (22.9%)	
\$35,000 – \$49,999	3863 (18.6%)	3866 (19.2%)	5085 (19.1%)	
\$50,000 – \$74,999	3962 (19.1%)	4045 (20.1%)	4981 (18.7%)	
\$75,000 +	3898 (18.8%)	4266 (21.2%)	4645 (17.4%)	
Disabled	564 (2.7%)	374 (1.9%)	516 (1.9%)	< 0.001
Recurrent pain and other medical conditions				
Joint pain or stiffness				
Severe	2221 (10.7%)	992 (4.9%)	1286 (4.8%)	< 0.001
Moderate	6031 (29.1%)	3592 (17.8%)	5773 (21.7%)	

Characteristics	Change in Pain Baseline to 3-Year Follow-Up				P-value
	Improved (N=20742)	None (N=20163)	Worsened (N=26647)		
Mild	9386 (45.3%)	11345 (56.3%)	14522 (54.5%)		
Low back pain					
Severe	1880 (9.1%)	891 (4.4%)	1094 (4.1%)		< 0.001
Moderate	4663 (22.5%)	2761 (13.7%)	4566 (17.1%)		
Mild	7286 (35.1%)	8293 (41.1%)	10831 (40.6%)		
Neck pain					
Severe	1091 (5.3%)	520 (2.6%)	753 (2.8%)		< 0.001
Moderate	3380 (16.3%)	2242 (11.1%)	3252 (12.2%)		
Mild	6454 (31.1%)	6757 (33.5%)	9118 (34.2%)		
Migraines or headaches					
Severe	773 (3.7%)	435 (2.2%)	565 (2.1%)		< 0.001
Moderate	2448 (11.8%)	1726 (8.6%)	2576 (9.7%)		
Mild	7495 (36.1%)	8062 (40.0%)	10460 (39.3%)		
Charlson index (mean [SD])	0.8 (1.1)	0.7 (1.0)	0.8 (1.1)		< 0.001
Number of non-pain medical conditions (mean [SD])	9.2 (4.7)	8.4 (4.5)	9.1 (4.6)		< 0.001
BMI (mean[SD])	27.5 (5.9)	26.8 (5.6)	27.7 (6)		< 0.001
Sedentary activity, hours per day (mean [SD]) [‡]	15.2 (4.2)	15.2 (4)	15.1 (4.1)		0.153
Pain, mean (SD) [§]	56 (22.7)	77 (21.3)	79 (19.1)		< 0.001
Physical functioning, mean (SD) [§]	76.7 (21.7)	83.2 (19.3)	80.3 (19.4)		< 0.001
BASELINE medication use					
Opioid use	634 (3.1%)	405 (2.0%)	542 (2.0%)		< 0.001
Other analgesic use ^{//}	9675 (46.6%)	8418 (41.7%)	11603 (43.5%)		< 0.001
HRT use	9730 (46.9%)	9548 (47.4%)	12504 (46.9%)		0.789
Psychosocial					
Depressed [†] (≥ 0.06 on shortened CES-D scale)	2677 (12.9%)	1887 (9.4%)	3097 (11.6%)		< 0.001
Ambivalence over emotional expressiveness [¶] , mean (SD)	3.0 (0.7)	3.0 (0.7)	3.0 (0.7)		< 0.001
Cynicism ^{**} , mean (SD)	3.8 (2.8)	3.5 (2.7)	3.8 (2.8)		< 0.001
Social support ^{††} , mean (SD)	35.8 (7.8)	36.5 (7.5)	35.6 (7.8)		< 0.001

§ From the SF-36, possible scores range from 0–100, higher scores indicate better health/functioning

// Use of acetaminophen, ibuprofen and other non-steroidal anti-inflammatories, aspirin, salicylate analgesics, other aspirin like analgesics, lidocaine and capsaicin creams

¶ Possible scores range from 1–5, higher scores indicating greater ambivalence in expressing negative emotions

** Possible scores range from 0–13, higher scores indicating greater cynicism

†† Possible scores range from 9–45, higher scores indicating greater support

* 6–7% missing

‡ 1–3% missing

‡ Hours sleeping, sitting or lying down

Table 2

Multinomial Logistic Regression Models*: Change in Pain[†] Among Post-Menopausal Women with Recurrent Pain Conditions

Independent Variables [‡]	Change Between Baseline and Year 3			
	Improved vs No Change	Worsened vs No Change	Odds Ratio (95% CI)	P-value
Depressed: ≥ 0.06 vs < 0.06 on shortened CES-D	0.91 (0.84, 0.99)	1.13 (1.05, 1.22)		0.001
Physical activity: +1 hour/day sitting or lying down	1.00 (0.99, 1.01)	1.00 (1.00, 1.01)		0.603
Ambivalence over emotional expressiveness construct (+1 unit)	1.00 (0.97, 1.04)	1.01 (0.98, 1.04)		0.716
Cynicism construct (+1 unit)	1.01 (1.00, 1.02)	1.01 (1.00, 1.02)		0.146
Social support construct (+1 unit)	1.00 (1.00, 1.01)	0.99 (0.99, 0.99)		<.001
Disabled	0.37 (0.31, 0.44)	1.03 (0.87, 1.23)		0.705
Charlson index (+1 unit)	0.97 (0.94, 0.99)	1.06 (1.04, 1.08)		<.001
Baseline hormone replacement therapy use	0.92 (0.87, 0.96)	1.15 (1.10, 1.20)		<.001
BMI: 25 – < 30 vs < 25	0.99 (0.94, 1.05)	1.20 (1.14, 1.26)		<.001
BMI: ≥ 30 vs <25	0.80 (0.75, 0.85)	1.54 (1.45, 1.63)		<.001
Number of non-pain symptoms (+1 unit)	0.97 (0.96, 0.97)	1.04 (1.03, 1.04)		<.001
Baseline opioid use vs no baseline opioid use	0.42 (0.36, 0.49)	1.13 (0.97, 1.32)		0.127
Baseline pain severity (+1 unit)	0.95 (0.95, 0.95)	1.01 (1.01, 1.02)		<.001

* Adjusted for age at screening, highest education level, family income, employment status-disabled, race/ethnicity

[†] Based on scores from SF-36 pain subscale

[‡] All variables from baseline interview

Table 3

Multinomial Logistic Regression Models*: Change in Physical Functioning[†] Among Post-Menopausal Women with Recurrent Pain Conditions

Independent Variables [‡]	Change Between Baseline and Year 3			
	Improved vs No Change	Worsened vs No Change	Odds Ratio (95% CI)	P-value
Depressed: ≥ 0.06 vs < 0.06 on shortened CES-D	0.99 (0.90, 1.08)	1.10 (1.01, 1.19)	1.10 (1.01, 1.19)	0.028
Physical activity: +1 hour/day sitting or lying down	0.99 (0.99, 1.00)	1.01 (1.00, 1.02)	1.01 (1.00, 1.02)	0.002
Ambivalence over emotional expressiveness construct (+1 unit)	1.06 (1.02, 1.10)	1.05 (1.02, 1.08)	1.05 (1.02, 1.08)	0.004
Cynicism construct (+1 unit)	1.00 (0.99, 1.01)	1.00 (0.99, 1.01)	1.00 (0.99, 1.01)	0.961
Social support construct (+1 unit)	1.00 (1.00, 1.00)	0.99 (0.99, 0.99)	0.99 (0.99, 0.99)	<.001
Disabled	0.39 (0.31, 0.49)	<.001	0.71 (0.57, 0.87)	0.001
Charlson index (+1 unit)	0.94 (0.92, 0.97)	<.001	1.05 (1.03, 1.08)	<.001
Baseline hormone replacement therapy use	1.02 (0.97, 1.08)	0.393	1.10 (1.05, 1.15)	<.001
BMI: 25 – <30 vs <25	1.07 (1.01, 1.14)	0.018	1.32 (1.25, 1.39)	<.001
BMI: ≥ 30 vs <25	0.99 (0.92, 1.06)	0.747	1.83 (1.71, 1.95)	<.001
Number of non-pain symptoms (+1)	1.00 (1.00, 1.01)	0.351	1.03 (1.03, 1.04)	<.001
Baseline opioid use only vs no baseline opioid use	0.88 (0.72, 1.08)	0.236	1.25 (1.04, 1.51)	0.020
Baseline physical functioning (+1 unit)	0.99 (0.98, 0.99)	<.001	0.95 (0.95, 0.95)	<.001

* Adjusted for age at screening, highest education level, family income, employment status-disabled, race/ethnicity

[†] Based on scores from SF-36 physical functioning subscale

[‡] All variables from baseline interview